United States VRAYLAR Market Drug Insight and Market Forecast - 2032

“VRAYLAR Market Drug Insight and Market Forecast - 2032” report provides comprehensive insights about VRAYLAR for Bipolar Depression (BD) in the United States. A detailed picture of the VRAYLAR for Bipolar Depression in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the VRAYLAR for Bipolar Depression. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VRAYLAR market forecast analysis for Bipolar Depression in the United States descriptive analysis such as SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Bipolar Depression.

Drug Summary

VRAYLAR (Cariprazine) is an oral capsule containing cariprazine as an active ingredient. It is approved in the US for schizophrenia, bipolar disorder, and bipolar depression. VRAYLAR was discovered and co-developed by Gedeon Richter Plc and is licensed by Allergan in the US.

Cariprazine is a dopamine-serotonin partial agonist. More specifically, cariprazine binds to D3 dopamine, D2 dopamine, and 5HT2B serotonin receptors with high potency and to 5HT1A serotonin and 5HT2A serotonin receptors with moderate potency, a profile that differs from both brexpiprazole and aripiprazole. Pharmacodynamic studies with cariprazine have shown that it acts as a partial agonist with a high binding affinity at dopamine D3, dopamine D2, and serotonin 5-HT1A receptors. Cariprazine demonstrated up to ~8-fold greater in vitro affinity for dopamine D3 vs. D2 receptors. Cariprazine also acts as an antagonist at serotonin 5-HT2B and 5-HT2A receptors with high and moderate binding affinity, respectively, as well as binds to the histamine H1 receptors.

• Dosage and Administration

General Dosing Information
VRAYLAR is administered orally once daily, with or without food. Because of the long half-life of cariprazine and its active metabolites, changes in dose will not be fully reflected in plasma for several weeks. Prescribers should monitor patients for adverse reactions and treatment responses for several weeks after starting VRAYLAR and after each dosage change.

Depressive Episodes Associated with BD-I (Bipolar Depression)
The starting dose of VRAYLAR is 1.5 mg once daily. Depending upon clinical response and tolerability, the dosage can be increased to 3 mg once daily on Day 15. The maximum recommended dosage is 3 mg once daily.

• Mechanism of Action

The mechanism of action of cariprazine in schizophrenia and bipolar I disorder is unknown. However, the efficacy of cariprazine could be mediated through a combination of partial agonist activity at central dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors. Cariprazine forms two major metabolites, desmethyl cariprazine (DCAR) and desmethyl cariprazine (DDCAR), that have in vitro receptor binding profiles similar to the parent drug.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the VRAYLAR description, mechanism of action, dosage and administration, research and development activities in Bipolar Depression.
• Elaborated details on VRAYLAR regulatory milestones and other development activities have been provided in this report.
• The report also highlights the VRAYLAR research and development activities in Bipolar Depression across the United States.
• The report also covers the patents information with expiry timeline around VRAYLAR.
• The report contains forecasted sales of for Bipolar Depression till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Bipolar Depression.
• The report also features the SWOT analysis with analyst views for VRAYLAR in Bipolar Depression.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

VRAYLAR Analytical Perspective

In-depth VRAYLAR Market Assessment

This report provides a detailed market assessment of VRAYLAR for Bipolar Depression in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.

VRAYLAR Clinical Assessment

The report provides the clinical trials information of VRAYLAR for Bipolar Depression covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Bipolar Depression is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VRAYLAR dominance.
• Other emerging products for Bipolar Depression are expected to give tough market competition to VRAYLAR and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VRAYLAR in Bipolar Depression.
• This in-depth analysis of the forecasted sales data of VRAYLAR from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VRAYLAR in Bipolar Depression.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of VRAYLAR?
• What is the clinical trial status of the study related to VRAYLAR in Bipolar Depression and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VRAYLAR development?
• What are the key designations that have been granted to VRAYLAR for Bipolar Depression?
• What is the forecasted market scenario of VRAYLAR for Bipolar Depression?
• What are the forecasted sales of VRAYLAR in the United States?
• What are the other emerging products available and how are these giving competition to VRAYLAR for Bipolar Depression?
• Which are the late-stage emerging therapies under development for the treatment of Bipolar Depression?

This product will be delivered within 2 business days.